Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:
• Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation
• Willing to give informed consent
Locations
Other Locations
Hong Kong Special Administrative Region
Queen Mary Hospital, Hong Kong
RECRUITING
Hong Kong
Contact Information
Primary
Desmond Yap, MD
desmondy@hku.hk
85222553879
Time Frame
Start Date: 2012-06-01
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 100
Treatments
Hepatorenal syndrome group
Patients with advanced cirrhosis who develope hepatorenal syndrome
Non-hepatorenal syndrome group
Patients with advanced cirrhosis who do not hepatorenal syndrome
Related Therapeutic Areas
Sponsors
Collaborators: The Hong Kong Society of Nephrology
Leads: The University of Hong Kong